The Motley Fool
27 Jun 2026, 15:47 UTC · 4h ago
Here's How Many Shares of Pfizer You Must Own to Get $5,000 in Yearly Dividends
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
27 Jun 2026, 15:47 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Pfizer faces the expiration of patents for key drugs including Eliquis, Ibrance, Xtandi, and Prevnar 13 within the next couple of years. — The loss of patent protection for these 'breadwinning' drugs threatens approximately one-third of the company's total revenue.
-0.60Pfizer has acquired five pharmaceutical companies since 2022 to bolster its oncology and anti-obesity portfolios. — Aggressive M&A activity creates a pipeline of potential blockbuster drugs to offset upcoming revenue losses.
+0.40Meaningful financial impacts from Pfizer's recent acquisitions are not expected to materialize until after 2028. — A long lead time before new products generate significant revenue creates a valuation gap and execution risk in the interim.
-0.30Continue reading
6 related stories
Search tags
Pfizer currently offers a high forward-looking dividend yield of approximately 7.1% to 7.27%. — High yields attract income-focused investors, providing a price floor despite growth concerns.
+0.20Which stocks this story touches
Despite facing a patent cliff, the company has a high dividend yield and a strategic acquisition plan to bring new blockbuster drugs to market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
1h ago
